GlassScriptPhysician profile
Carrie B Voedisch
NPI 1104903566
$31,843.69
in general payments reported to CMS, 2019-2025
15 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.80 · 2022: $280 · 2023: $797 · 2024: $12K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $8,222 · Food and Beverage: $4,067 · Consulting Fee: $825 · Education: $40.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,375.00 |
| Travel and Lodging | $8,222.47 |
| Food and Beverage | $4,067.03 |
| Consulting Fee | $825.00 |
| Education | $40.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,781.89 | 2022-2025 | |
| Janssen Biotech, INC. | $226.03 | 2023-2025 | Stelara, Tremfya |
| Ironwood Pharmaceuticals, INC | $145.01 | 2021-2024 | Linzess |
| Ardelyx, INC. | $141.91 | 2023-2025 | Ibsrela |
| Pfizer INC. | $93.63 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.33 | 2024-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.24 | 2023-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $65.53 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $64.14 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $56.26 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $24.52 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $23.13 | 2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $22.62 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $22.40 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $21.05 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Voedisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.